Compare Abbott Laboratories (ABT) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Freeport-McMoRan Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Freeport-McMoRan Inc trades at $57.47 (market cap $85.29B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | FCX | |
|---|---|---|
Market Cap | $166.94B | $85.29B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $71.73 |
52-Week Low | $82.57 | $35.34 |
Enterprise Value | $193.69B | $91.95B |
Dividend Yield | 2.63% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
FCX trades at $59.27, down 2.77% on the day, with a bearish technical signal but strong fundamentals including a 10.34% net income margin and consistent earnings beats. Recent news highlights copper demand growth from AI and energy transitions, positioning FCX as a key player. Cash flow trends show improving operational performance, though net cash flow remains negative due to heavy investments.
Outlook is positive with a consensus price target of $71.81, implying 21% upside, supported by robust copper demand and expansion projects. Risks include commodity price volatility and execution challenges. Analyst sentiment is bullish with 59% buy ratings, but investors should monitor debt levels and global economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
